Guangdong Anno Pharmaceutical

Guangdong Anno Pharmaceutical is a comprehensive pharmaceutical enterprise based in Shantou, China, focusing on the integration of drug R&D, production, and sales. Founded in 2003, the company has established a robust portfolio primarily centered on chemical drugs for cardiovascular diseases, digestive system disorders, and anti-infective treatments. It operates modern manufacturing bases that comply with national GMP standards, ensuring high-quality production of both active pharmaceutical ingredients (APIs) and finished dosage forms. Anno Pharmaceutical is publicly traded on the National Equities Exchange and Quotations (NEEQ) under the ticker 833461. The company's strategic focus includes the development of high-end generic drugs and the gradual transition toward innovative drug discovery to enhance its competitive position in the healthcare market. Its key products include Rabeprazole Sodium and various antihypertensive medications which are widely distributed across the Chinese hospital and retail sectors.